Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors: Ewing sarcoma and PNET

Autor: Djordjije Saranovic, Dragana Sobic Saranovic, Lejla Paripovic, Slobodanka Beatovic, Vera Artiko, Isidora Grozdic Milojevic, Marina Nikitovic, Jelena Saponjski
Rok vydání: 2019
Předmět:
Adult
Male
Adolescent
Bone Neoplasms
Sarcoma
Ewing
Sensitivity and Specificity
030218 nuclear medicine & medical imaging
Cohort Studies
03 medical and health sciences
Young Adult
0302 clinical medicine
Fluorodeoxyglucose F18
Predictive Value of Tests
Positron Emission Tomography Computed Tomography
Biopsy
medicine
Humans
Neuroectodermal Tumors
Primitive
Radiology
Nuclear Medicine and imaging
Progression-free survival
Child
Retrospective Studies
medicine.diagnostic_test
Proportional hazards model
business.industry
Soft tissue
Reproducibility of Results
General Medicine
medicine.disease
Progression-Free Survival
Treatment Outcome
030220 oncology & carcinogenesis
Primitive neuroectodermal tumor
Child
Preschool
Disease Progression
Fdg pet ct
Female
Sarcoma
Post treatment
Radiopharmaceuticals
Nuclear medicine
business
Zdroj: European journal of radiology. 129
ISSN: 1872-7727
Popis: Purpose To determine if post-treatment F-18 FDG PET/CT results (overall positive findings, specific localizations) are independent predictors of disease progression in young patients with Ewing sarcoma and Primitive neuroectodermal tumor. Method A consecutive sample of 48 patients (age 14 ± 5 years, 32 male) was referred to F-18 FDG PET/CT for the suspected progression of Ewing sarcoma (39 patients) and Primitive neuroectodermal tumor (PNET) (9 patients) and followed-up clinically for 4.3 ± 2.3 years after F-18 FDG PET/CT (range 1–8 years). The diagnostic value of F-18 FDG PET/CT was determined in comparison to the biopsy. Kaplan-Meier analysis was used to compare progression-free survival between the groups with positive and negative F-18 FDG PET/CT findings. Variables included in the Cox regression for predicting the progression-free survival were sex, age, F-18 FDG PET/CT findings, MDCT findings, and MR ratio. Results F-18 FDG PET/CT findings were positive in 32 (67 %) patients (sensitivity 93.7 %, specificity 87.5 %, accuracy 91.7 %) with an average SUVmax of 5.8 ± 3.2 (95 % CI 4.8–7.1). The progression-free survival was significantly lower (p = 0.001) in patients with positive F-18 FDG PET/CT findings (median 28 months) and when recurrence was located in bones, soft tissues, and muscles (p = 0.02, median 21 months). The significant predictors of the disease progression were the overall positive F-18 FDG PET/CT findings (HR 8.36, p = 0.004) and, specifically, the local recurrence in the bone with infiltration of soft tissue/muscles (HR 4.08, p = 0.003). Conclusion Post-treatment F-18 FDG PET/CT findings are useful for predicting the progression of Ewing sarcoma and PNET and should be included in the clinical monitoring of these patients.
Databáze: OpenAIRE
Externí odkaz: